1. Dijagnostika i prvo liječenje karcinoma pluća
Pacijentu Lu dijagnosticiran je adenokarcinom pluća i metastaze u limfnim čvorovima 26. kolovoza 2005. Lijeva donja lobektomija učinjena je 22. rujna 2005. Karboplatin u kombinaciji s taksoterom korišten je 4 puta nakon operacije. 3. kolovoza 2007. zbog pleuralnog izljeva potvrđen je recidiv dijagnoze te je liječena Tarcevom (broj ciklusa nije poznat). Dana 8. siječnja 2008. na ponovnom pregledu utvrđeno je napredovanje karcinoma, a zatim je prekinuto liječenje Tarcevom i započeto liječenje Libitom u trajanju od 16 ciklusa. Istodobno je pronađena vertebralna metastaza kuka te su učinjena 4 ciklusa Zetai.
2. Prvi put da sudjelujete u kliničkim ispitivanjima, stanje je pod kontrolom.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. U drugom kliničkom ispitivanju, tumor je očito nestao.
On August 6, 2012, Mr. Lu participated in the AP26113 drug kliničko ispitivanje at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the tumor u mozgu decreased and became large.
4. Otkrijte rijetke genske mutacije i veselite se sudjelovanju u novim kliničkim ispitivanjima
Ponovni pregled u srpnju 2014., PET cijelog tijela pokazao je: lezije na mozgu bile su u osnovi stabilne, a na prsima je evidentan napredak. Dana 12. svibnja 2014., sumnjive anti-AP26113 limfne (3 stanice, najveće 1.1 cm) kultivirane stanične linije obavljene su u Općoj bolnici Massachusetts i nastavile su uzimati AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastom and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody imunoterapija phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
